A new review suggests that the menopausal transition represents a critical period for Alzheimer’s disease prevention in women, potentially shifting focus to early detection, gender-specific risk factors, and more personalized care.
Expert review: Women’s midlife: The front lines of Alzheimer’s disease prevention. Image credit: izzuanroslan / Shutterstock
In a recent review published in clinical research journalLisa Mosconi, Ph.D., author of Neuroscientist and women’s brain health expert, investigated how midlife hormonal changes and neuroendocrine aging influence Alzheimer’s disease (AD) risk in women and identified opportunities for gender-specific early prevention strategies.
Why are women at higher risk of Alzheimer’s disease?
Almost two-thirds of people with Alzheimer’s disease are women, raising important questions about why women are more vulnerable. Traditionally, this has been thought to be related to long life expectancy, but new evidence suggests a deeper biological cause. Hormonal changes during midlife, especially menopause, can alter brain biology and metabolism, potentially contributing to amyloid plaques and tau tangles, important biological markers of Alzheimer’s disease.
It is estimated that by 2050, more than 1.2 billion women will experience menopause. Therefore, it is important to understand these changes. At present, there are not many studies focusing on sex-specific mechanisms. Therefore, further research on these topics is urgently needed.
Epidemiology and gender differences in Alzheimer’s disease
Alzheimer’s disease affects more than 55 million people worldwide and is predicted to rise to more than 150 million by 2050. Women account for nearly two-thirds of these cases. While aging remains the strongest risk factor, female gender is the strongest risk factor for late-onset Alzheimer’s disease later in life. However, although pooled meta-analyses support a slight excess incidence in women, some studies report no difference in incidence, so some epidemiological debates remain unresolved.
This difference is not solely determined by lifespan, as biological, hormonal, and social factors also contribute. Remarkably, AD is now recognized as a disease that occurs decades before onset, primarily in middle age. This shifts the focus to the earlier stages of life, especially for women.
Brain and hormonal changes due to menopause
Menopause is a major hormonal change in which estrogen levels decrease while follicle-stimulating hormone (FSH) and luteinizing hormone (LH) rise. Estrogen protects the brain by reducing inflammation, increasing neuronal survival, supporting non-amyloidogenic processing, and reducing amyloid-beta-related neurotoxicity. As estrogen levels decrease and FSH and LH levels increase during menopause, these changes may promote processes associated with the development of AD.
Brain imaging studies have shown that postmenopausal women have higher amyloid-beta deposits, decreased brain glucose metabolism, and decreased gray matter volume compared to premenopausal women and men. These results suggest that menopause may act as a biological tipping point in brain aging, but some findings may also partially reflect aging itself, not just menopause.
Reproductive health factors and dementia risk
There are several reproductive health factors that affect your risk of Alzheimer’s disease. Early menopause, especially before age 45, is associated with an increased risk of dementia. Ovariectomy (removal of the ovaries) before natural menopause may increase long-term dementia risk, with the greatest excess risk seen in younger age groups, particularly those under 45 years.
It has also been suggested that the risk of dementia is associated with a shorter reproductive period (the time between menarche and menopause), perhaps due to less exposure to estrogen, although research remains mixed.
Women who have experienced polycystic ovary syndrome (PCOS) may experience early onset of dementia. Parity (number of births) shows a complex relationship. For example, having one to four children may reduce your risk, but having five or more may increase your risk.
Cognitive symptoms and early signals in midlife
Many women report memory loss, difficulty concentrating, or mental fogginess during perimenopause. Subjective cognitive decline (SCD) is considered typical of the aging process. However, it can signal the beginning of cognitive decline.
Empirical evidence supports this association through various brain imaging analyses. Brain scans have shown that women with SCD have reduced structural integrity, particularly in brain regions known to be affected by Alzheimer’s disease, and also reduced functional connectivity between brain regions, along with reduced levels of energy production in brain cells, although the mechanisms linking menopause-related SCD and Alzheimer’s disease are still being studied.
Vasomotor symptoms, which occur frequently, especially during sleep, have also emerged as an understudied midlife factor associated with Alzheimer’s disease-related risk, with the review citing studies linking them to increased white matter signal intensity and less favorable plasma amyloid biomarker profiles.
Timing of hormone therapy and prevention of Alzheimer’s disease
Menopausal hormone therapy (MHT), including estrogen therapy (ET) or combined estrogen-progestogen therapy (EPT), has been widely studied for its potential role in the prevention of Alzheimer’s disease.
Trials such as the Women’s Health Initiative Memory Study (WHIMS) have demonstrated that older adults (65-79 years) are at increased risk of dementia when they begin MHT. But new evidence suggests that timing matters. Starting MHT near menopause may reduce the risk of Alzheimer’s disease by 11% to 30%, but these findings are primarily from observational studies and should be interpreted with caution due to potential bias and confounding.
This concept is known as the “timing hypothesis.” The paper proposes that hormone therapy is only beneficial if started at a critical time, usually within 10 years after menopause. If treatment is started too late, it may be ineffective or have harmful effects.
Although current guidelines do not recommend MHT to prevent cognitive decline or dementia in the general population, estrogen therapy near menopause may help preserve cognitive function in women with early menopause, especially after oophorectomy.
Genetic, lifestyle, and health disparities
The apolipoprotein E ε4 (APOE ε4) allele is considered the strongest genetic risk factor for AD. However, women may be at higher risk than men. Many common cardiovascular diseases, physical inactivity, and sleep deprivation become more common after menopause, and all three are associated with increased risk of cognitive impairment and may account for up to 45% of Alzheimer’s disease cases worldwide.
Differences in health status also affect the likelihood of developing Alzheimer’s disease. Black and Hispanic women have more menopausal symptoms and higher rates of dementia than other groups, likely due to a combination of biological and socio-environmental factors, but further research is needed to determine whether these differences reflect underlying biological vulnerabilities or other causes.
Precise prevention and early detection strategies
Advances in biomarkers such as blood-based biomarkers (BBB), cerebrospinal fluid (CSF) analysis, and positron emission tomography (PET) imaging have made it possible to detect Alzheimer’s disease pathology years before symptoms appear.
This opens the door to early intervention. By identifying women at risk in midlife, health systems can implement targeted prevention strategies such as hormone therapy, lifestyle changes, and individualized treatments based on genetic and hormonal profiles.
This review also highlights that current prevention frameworks are primarily aggregated by sex and do not take into account female-specific neuroendocrine and reproductive risk factors, and thus may underestimate women’s cumulative risk burden.
Conclusions and future research directions
The study concludes that women’s risk of Alzheimer’s disease is likely shaped in part by midlife neuroendocrine changes, not just aging. Hormonal changes during menopause have a major impact on brain health, as they can contribute to brain changes associated with Alzheimer’s disease and an increased risk of neurodegenerative vulnerability.
Early menopause, reproductive history, subjective cognitive decline, and vasomotor symptoms are important indicators of possible increased risk, but are not definitive predictors in themselves. Research shows that hormone therapy may have benefits, but its effectiveness may depend on timing and a woman’s biology.
This review demonstrates the need for prevention approaches that are gender-specific, supported by more powerful biomarkers, and tailored to women’s biology. This review also highlights that more long-term, biomarker-based causal studies are needed to treat menopause-related mechanisms as definitively established drivers of Alzheimer’s disease.
